title: Current and future oral systemic therapies for psoriasis.
abstract: For patients with moderate to severe psoriasis, there is a large range of variably effective and safe oral, systemic medications. With appropriate monitoring, these therapies may be used as either monotherapy or in combination with other therapies. Newer drugs in the research pipeline hold significant promise.
authors.affiliation: Department of Dermatology, University of Connecticut Health Center, Farmington, CT, USA.
authors.forename: John B
authors.initials: JB
authors.lastname: Kelly
authors.affiliation: St Vincent's Hospital Melbourne, The University of Melbourne, Victoria, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: Foley
authors.affiliation: Department of Dermatology, University of Connecticut Health Center, Farmington, CT, USA; Probity Medical Research, Waterloo, Ontario, Canada. Electronic address: strober@uchc.edu.
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Strober
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000963:Antimetabolites; D005650:Fumarates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D007641:Keratolytic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D012460:Sulfasalazine; D013792:Thalidomide; D016572:Cyclosporine; C479163:tofacitinib; D013866:Thioguanine; D000077339:Leflunomide; D009173:Mycophenolic Acid; D017255:Acitretin; C505730:apremilast; D006918:Hydroxyurea; D008727:Methotrexate
keywords: Acitretin; Apremilast; Cyclosporine; Methotrexate; Mycophenolate mofetil; Psoriasis; Tofacitinib